Progress Toward a Better Predictor of Remission in Anti-Phospholipase A2 Receptor-Associated Membranous Nephropathy.
作者信息
Nachman Patrick H
机构信息
University of Minnesota Twin Cities School of Medicine, Minneapolis, Minnesota.
出版信息
Clin J Am Soc Nephrol. 2025 May 15;20(6):763-765. doi: 10.2215/CJN.0000000737.
Abstract
摘要
相似文献
1
Progress Toward a Better Predictor of Remission in Anti-Phospholipase A2 Receptor-Associated Membranous Nephropathy.抗磷脂酶A2受体相关膜性肾病缓解更好预测指标的研究进展
Clin J Am Soc Nephrol. 2025 May 15;20(6):763-765. doi: 10.2215/CJN.0000000737.
2
Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy: A Validation Study.PLA2R 相关膜性肾病的无创诊断：一项验证性研究。
Clin J Am Soc Nephrol. 2021 Dec;16(12):1833-1839. doi: 10.2215/CJN.05480421. Epub 2021 Nov 15.
3
Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.成人肾病综合征中原发性膜性肾病的免疫抑制治疗。
Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4.
4
Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome.纤维蛋白原-白蛋白比值预测伴有肾病综合征的磷脂酶 A2 受体相关膜性肾病的治疗反应。
Ren Fail. 2024 Dec;46(1):2359024. doi: 10.1080/0886022X.2024.2359024. Epub 2024 Jun 4.
5
Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.三个月时抗磷脂酶 A2 受体抗体阴性预测原发性膜性肾病缓解。
Ren Fail. 2022 Dec;44(1):258-268. doi: 10.1080/0886022X.2022.2033265.
6
Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.抗磷脂酶 A2 受体 1 抗体和抗胱氨酸丰富域抗体在膜性肾病中的识别作用及利妥昔单抗疗效：一项前瞻性队列研究。
Am J Kidney Dis. 2024 May;83(5):588-600.e1. doi: 10.1053/j.ajkd.2023.10.013. Epub 2023 Dec 25.
7
Long-term Exposure to Complementary and Alternative Medicine Leads to Neural Epidermal Growth Factor-like 1 Membranous Nephropathy.长期接触补充和替代医学导致神经表皮生长因子样1膜性肾病。
J Assoc Physicians India. 2025 May;73(5):81-82. doi: 10.59556/japi.73.0960.
8
Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy.原发性抗磷脂综合征伴抗磷脂酶 A2 受体抗体阳性的膜性肾病。
BMC Nephrol. 2020 May 24;21(1):196. doi: 10.1186/s12882-020-01856-z.
9
M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.原发性膜性肾病患者的M型磷脂酶A2受体自身抗体与肾功能
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1883-90. doi: 10.2215/CJN.03850414. Epub 2014 Sep 29.
10
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.每月小剂量利妥昔单抗治疗原发性抗 PLA2R 阳性膜性肾病：一种个体化方法。
BMC Nephrol. 2023 May 26;24(1):146. doi: 10.1186/s12882-023-03206-1.
本文引用的文献
1
Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy: A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials.预测抗磷脂酶A2受体抗体相关膜性肾病的缓解：GEMRITUX、MENTOR和STARMEN试验的二次分析
Clin J Am Soc Nephrol. 2025 Apr 14;20(6):854-865. doi: 10.2215/CJN.0000000694.
2
Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop.抗磷脂酶A2受体1时代膜性肾病治疗的临床试验设计：NephCure膜性肾病研讨会结果
Glomerular Dis. 2025 Mar 14;5(1):133-141. doi: 10.1159/000544808. eCollection 2025 Jan-Dec.
3
Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop.抗磷脂酶A2受体（anti-PLA2R）时代膜性肾病治疗临床试验的设计：肾病研究基金会膜性肾病研讨会结果
Kidney Int. 2025 May;107(5):809-815. doi: 10.1016/j.kint.2024.09.020. Epub 2025 Mar 14.
4
Membranous nephropathy-diagnosis and identification of target antigens.膜性肾病——诊断和靶抗原鉴定。
Nephrol Dial Transplant. 2024 Mar 27;39(4):600-606. doi: 10.1093/ndt/gfad227.
5
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.STARMEN 试验表明，在原发性膜性肾病中，与他克莫司和利妥昔单抗序贯治疗相比，皮质类固醇和环磷酰胺交替治疗更具优势。
Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7.
6
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.利妥昔单抗或环孢素治疗膜性肾病。
N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427.
7
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.利妥昔单抗治疗重度膜性肾病：一项为期6个月的试验及延长随访
J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449. Epub 2016 Jun 27.
8
Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.完全缓解和部分缓解作为膜性肾病的替代终点
J Am Soc Nephrol. 2015 Dec;26(12):2930-7. doi: 10.1681/ASN.2015010091. Epub 2015 Jun 15.
9
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.利妥昔单抗诱导的抗 PLA2R 自身抗体耗竭可预测膜性肾病的反应。
J Am Soc Nephrol. 2011 Aug;22(8):1543-50. doi: 10.1681/ASN.2010111125. Epub 2011 Jul 22.
10
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.M型磷脂酶A2受体作为特发性膜性肾病的靶抗原
N Engl J Med. 2009 Jul 2;361(1):11-21. doi: 10.1056/NEJMoa0810457.
Zotero 插件